Barclays raised the firm’s price target on Chemours (CC) to $23 from $21 and keeps an Equal Weight rating on the shares post the Q3 report. The company’s “stabilizing results and strategy were clear positives,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CC: